ACLARIS THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

20 يناير 2026 10:00:06 بحسب NetDania Notify

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

12 يناير 2026 06:55:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

06 يناير 2026 06:59:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

19 ديسمبر 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

25 نوفمبر 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

06 نوفمبر 2025 06:59:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

29 أكتوبر 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

30 سبتمبر 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

09 سبتمبر 2025 07:00:08 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

27 أغسطس 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

07 أغسطس 2025 06:59:33 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

29 يوليو 2025 16:01:47 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Transition

28 يوليو 2025 08:45:00 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

30 يونيو 2025 09:31:48 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

26 يونيو 2025 16:01:27 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

23 يونيو 2025 06:59:36 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

02 يونيو 2025 06:59:53 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

28 مايو 2025 09:20:15 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

09 مايو 2025 07:00:19 بحسب Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 مايو 2025 06:50:51 بحسب Nasdaq GlobeNewswire